Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
This study tests a targeted cancer-fighting medication called Talazoparib for people with metastatic breast cancer that has spread. It specifically looks at cancers with a somatic BRCA mutation, which means a gene change found in the tumor or blood rather than one passed down from parents.
You may be able to join if you have breast cancer that has spread to other parts of your body, features an acquired BRCA gene mutation, and you have not previously taken PARP inhibitor medications. If you have triple-negative breast cancer, your cancer must have progressed after at least one prior chemotherapy treatment.
Participants will receive the study medication, Talazoparib, which is designed to target specific cancer cells. Your health team will closely monitor you and your response to the treatment throughout the study.
This study is currently recruiting participants and is taking place at locations in San Francisco, California; Atlanta, Georgia; and Chicago, Illinois.
- 1Evaluating the targeted medication Talazoparib
- 2For metastatic breast cancer with an acquired BRCA mutation
- 3Currently recruiting at multiple U.S. locations
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.